ProMIS Neurosciences (PMN) Operating Income (2021 - 2026)
ProMIS Neurosciences' (PMN) quarterly Operating Income came in at -$8.6 million in Q1 2026, down 15.88% YoY from -$10.3 million in Q1 2025, and up 19.99% on a QoQ basis from -$10.8 million in Q4 2025.
ProMIS Neurosciences (PMN) Operating Income (2021 - 2026) Analysis & Trends
ProMIS Neurosciences (PMN) has 6 years of Operating Income data on file, last reported at -$8.6 million in Q1 2026.
- Quarterly Operating Income fell 15.88% year-over-year to -$8.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$41.4 million (down 100.79% YoY) and the FY2025 annual result came in at -$40.2 million, down 138.89% from the prior year.
- Operating Income climbed to -$8.6 million in Q1 2026, from -$10.8 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$2.5 million in Q3 2023 to a low of -$11.8 million in Q3 2025.
- A 5-year average of -$6.1 million and a median of -$5.0 million in 2023 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2022 — Operating Income plunged 340.07% — and 2023, when it jumped 58.42%.
- Tracing PMN's Operating Income over 5 years: stood at -$8.5 million in 2022, then soared by 54.54% to -$3.9 million in 2023, then plunged by 54.92% to -$6.0 million in 2024, then plunged by 80.01% to -$10.8 million in 2025, then grew by 19.99% to -$8.6 million in 2026.
- The last three Operating Income figures came in at -$8.6 million (Q1 2026), -$10.8 million (Q4 2025), and -$11.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | ProMIS Neurosciences | 135.22 Mn | 81.75 Mn | - | -12.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12.27 Mn |
| Mar 31, 2026 | -8.64 Mn |
| Dec 31, 2025 | -10.80 Mn |
| Sep 30, 2025 | -11.75 Mn |
| Jun 30, 2025 | -10.18 Mn |
| Mar 31, 2025 | -7.46 Mn |
| Dec 31, 2024 | -6.00 Mn |
| Sep 30, 2024 | -4.43 Mn |
| Jun 30, 2024 | -2.71 Mn |
| Mar 31, 2024 | -3.68 Mn |
| Dec 31, 2023 | -3.87 Mn |
| Sep 30, 2023 | -2.52 Mn |
| Jun 30, 2023 | -2.90 Mn |
| Mar 31, 2023 | -4.97 Mn |
| Dec 31, 2022 | -8.52 Mn |
| Sep 30, 2022 | -6.05 Mn |
| Jun 30, 2022 | -4.86 Mn |
| Mar 31, 2022 | -3.94 Mn |
| Dec 31, 2021 | -4.55 Mn |
| Sep 30, 2021 | -2.07 Mn |